Swedish IQT Buys Kigen for $10.8B

Molecular Testing and Diagnostics Company "KiaGen" announced an acquisition agreement by Swedish investment firm "EQ T" valued at approximately $10.78 billion, with a premium of 8.6% over the last share price. This deal marks the end of years of speculation about the takeover of the European diagnostics company, amid rising interest from private equity firms in the healthcare sector driven by the increasing demand for molecular testing and diagnostics.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل